Threshold

<![if lt IE 4]> <script src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=js" type="text/javascript"> </script> <noscript> <a href="http://servedbyadbutler.com/go2/;ID=101843;size=468x60;setID=73431"> <img src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=img" border="0" height="60" width="468" alt=""></a> </noscript><![endif]>

BioCentury: Hypoxic Depth Charge

By WallStArb - Posted on May 31st, 2009

Tagged:

• Product Development - Hypoxic Depth Charge - Threshold Pharmaceuticals has preliminary Phase I/II data showing that its TH-302 hypoxia-activated prodrug (HAP) could kill cells in hypoxic regions of tumors where chemotherapy doesn't reach.
From BioCentury - http://www.biocentury.com

By Aaron Bouchie
Senior Writer

Average:

Your rating: None Average: 5 (1 vote)

User login

Navigation

Who's new

Eurofehouff
unioldton
Cragun
pierpamyRer
Kceirvhpm

Copyright © 1997 - 2008 Financial Chat, Inc. All Rights Reserved
<![if lt IE 4]> <script src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=js" type="text/javascript"> </script> <noscript> <a href="http://servedbyadbutler.com/go2/;ID=101843;size=468x60;setID=73431"> <img src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=img" border="0" height="60" width="468" alt=""></a> </noscript><![endif]>

Threshold

BioCentury: Hypoxic Depth Charge

User login

Navigation

site info

Who's online

Online users

Who's new